Accelerate Diagnostics

Tucson, Arizona, US All United States companies → — Founded 1982

Medical Device / Hardware Point-of-Care Diagnostics

Critical Care Infectious Disease Laboratory Medicine

N/A (formerly public, acquired by Bruker Corporation after Chapter 11 bankruptcy in 2025) — N/A (due to acquisition and bankruptcy; the company accumulated $718.9 million in losses since inception)

Claim this company

Products

Accelerate Pheno System

Accelerate Diagnostics

Lab & Diagnostics

The Accelerate Pheno System is a rapid, automated in vitro diagnostic platform for pathogen identification and antimicrobial susceptibility testing directly from positive blood cultures, significantly reducing turnaround time for critical infectious disease diagnoses. It is not an AI tool for a physician directory.

Contact vendor for pricing

See all 1 product →

About Accelerate Diagnostics

Accelerate Diagnostics was an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. Their primary offerings included the Accelerate Pheno® system and Accelerate PhenoTest® BC kit, which utilized automated fluorescence in situ hybridization and morphokinetic cellular analysis to rapidly identify bacterial infections and determine antimicrobial susceptibility directly from positive blood cultures. This technology aimed to significantly reduce the time required for optimal antibiotic therapy from days to approximately seven hours, thereby enabling earlier, targeted treatment and potentially improving patient outcomes and reducing healthcare costs in critical conditions like sepsis. The company also developed the Accelerate Arc™ system for automated sample preparation for direct microbial identification, and the Accelerate WAVE™ system, designed for even faster phenotypic AST results.

However, Accelerate Diagnostics, Inc. filed for Chapter 11 bankruptcy on May 8, 2025, after accumulating substantial losses. Subsequently, its assets were acquired by Bruker Corporation in November 2025. While the core diagnostic technologies and their applications in combating antibiotic resistance and sepsis remain relevant, the company no longer operates as an independent entity.

Regarding the user’s mention of “healthcare AI company,” the provided search results for Accelerate Diagnostics primarily describe its focus on rapid in vitro diagnostics and automation, rather than explicitly highlighting Artificial Intelligence as a core technology or primary offering within its diagnostic systems. The company’s product descriptions emphasize specific biological and automated testing methodologies.

Focus Areas

Rapid pathogen identification Antimicrobial Susceptibility Testing (AST) Antibiotic Resistance Sepsis

Business Intelligence

Key Investors	Indaba Capital Management, Crabtree Partners
Partnerships	BD (Becton, Dickinson and Company), Bruker Corporation (acquired assets)
Acquisitions	Assets acquired by AST Revolution, LLC (an affiliate of Indaba Capital Management), which was subsequently acquired by Bruker Corporation.
Technology	Accelerate Pheno system (automated fluorescence in situ hybridization, morphokinetic cellular analysis), Accelerate Arc system (automated positive blood culture sample preparation), Accelerate WAVE system (holographic imaging technology for rapid AST)
FDA Clearances	2 (Accelerate Pheno system and PhenoTest BC Kit; Accelerate Arc system and BC kit) cleared products (estimated)

What Physicians Need to Know

Rapid Pathogen Identification

Accelerate Diagnostics specialized in identifying pathogens directly from positive blood cultures in approximately two hours using their Accelerate Phenou2122 system, which employed fluorescence in situ hybridization (FISH) technology. Their Accelerate Arcu2122 system also enabled rapid microbial identification from positive blood cultures by automating sample preparation for use with MALDI Biotyperu00ae CA Systems.

Antimicrobial Susceptibility Testing (AST)

The company's Accelerate Phenou2122 system provided phenotypic antimicrobial susceptibility testing (AST) results in approximately five hours, directly from positive blood cultures, significantly reducing the time to results compared to traditional methods. The Accelerate WAVEu2122 system, which was submitted for FDA clearance, aimed to deliver even faster AST results, averaging 4.5 hours, utilizing holographic or advanced optical imaging.

Antibiotic Resistance

Accelerate Diagnostics' core mission was to combat antibiotic resistance by providing rapid and accurate diagnostic information. Their systems were designed to enable clinicians to optimize antibiotic selection and dosage specific to individual patients days earlier, thereby helping to slow the spread of antimicrobial resistance.

Sepsis Management

The company's technologies were critical in the fight against sepsis, a life-threatening condition where time to effective therapy is a primary determinant of mortality. By providing rapid pathogen identification and AST results, their systems aimed to enable quicker administration of optimal antibiotic therapy, leading to improved patient outcomes and reduced hospital length of stay.

Physician Tip

For physicians, Accelerate Diagnostics' systems, particularly the Accelerate Phenou2122 system, offered a significant advantage by dramatically reducing the turnaround time for pathogen identification and antimicrobial susceptibility testing from days to approximately seven hours. This speed was crucial for guiding timely and targeted antibiotic therapy, especially in critical conditions like sepsis, leading to improved patient outcomes, reduced hospital stays, and a more effective approach to antimicrobial stewardship. The Accelerate Arcu2122 system further streamlined the workflow for labs utilizing MALDI-TOF for identification. nn**Important Note:** Accelerate Diagnostics, Inc. filed for Chapter 11 bankruptcy in May 2025, and its assets were subsequently sold in September 2025 as part of a liquidation plan. While their technology was innovative, the company as it existed is no longer operating. Physicians should be aware that support and availability of these specific systems may be impacted, and any future offerings would likely be under a new entity (e.g., AST Revolution, which acquired some assets).

The Accelerate Arcu2122 system was designed for integration with Bruker's MALDI Biotyperu00ae CA System, providing an automated sample preparation platform for direct microbial identification. The Accelerate Phenou2122 system was a standalone, fully automated in vitro diagnostic platform. However, due to Accelerate Diagnostics' bankruptcy and asset sale in 2025, the status of ongoing integrations and product support should be verified with the acquiring entity or relevant distributors.

At a glance

Founded 1982

HQ Tucson, Arizona, US · United States

Team size 107 (as of December 31, 2024, prior to acquisition)

CEO Jack Phillips (CEO until the company's acquisition in 2025)

Funding N/A (formerly public, acquired by Bruker Corporation after Chapter 11 bankruptcy in 2025) — N/A (due to acquisition and bankruptcy; the company accumulated $718.9 million in losses since inception)

FDA clearances 2 (Accelerate Pheno system and PhenoTest BC Kit; Accelerate Arc system and BC kit) (estimated)

Products 1

Products by Accelerate Diagnostics

1 product in the directory

Accelerate Pheno System

Accelerate Diagnostics

Lab & Diagnostics

Contact vendor for pricing

What the Web Says

Accelerate Diagnostics is an in-vitro diagnostics company focused on rapid diagnosis of serious infections, particularly through its Accelerate Pheno system and PhenoTest BC kit. These products aim to reduce the time to identify infectious pathogens and determine antibiotic susceptibility from days to hours, which can improve patient outcomes and lower healthcare costs. However, the company has faced significant challenges, including filing for Chapter 11 bankruptcy in May 2025 and planning to sell substantially all its assets, which is expected to involve workforce reductions.

Overall: Negative

Strengths

Products provide rapid identification and antibiotic susceptibility testing (AST) for infectious pathogens, significantly reducing turnaround time.
The Accelerate Pheno system has shown improvements in clinical outcomes, such as time to optimal therapy and hospital length of stay.
Employees have noted a great mission and a group of like-minded individuals striving to accelerate diagnostics.
Some employees found it a great working environment with good people.
Offers solutions for fast sepsis testing.

Limitations

The company filed for Chapter 11 bankruptcy in May 2025 and is selling most of its assets.
Expected workforce reductions due to restructuring.
Employee reviews on Indeed mention being overworked, underappreciated, and underpaid with extremely low salaries and rare raises.
Poor morale and culture have been cited by employees.
Unrealistic expectations and an unprofessional environment have been reported.
Job security and advancement opportunities are rated poorly by employees.

Based on reviews from: Comparably, Indeed.com, Clinical Lab Products, PR Newswire, AnnualReports.com, Fintel, Reddit, Xtalks

Last updated: 2026-07-17

Videos

News, demos, and interviews about Accelerate Diagnostics.

Loading videos...

Videos load interactively. If none appear, search YouTube for Accelerate Diagnostics →

View all on YouTube

Press & Coverage

BioSpace

Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

Accelerate Diagnostics submitted its Accelerate WAVEu2122 system and a gram-negative positive blood culture test kit to the FDA for 510(k) clearance, aiming to provide rapid antimicrobial susceptibility testing directly from positive blood cultures and bacterial isolate colonies.

2025-03

PRNewswire (via BioSpace)

Accelerate Diagnostics Announces a Successful Completion of its WAVEu2122 Pre-Clinical Trial

Accelerate Diagnostics announced the successful completion of its WAVE pre-clinical trial, with the system designed to deliver rapid antimicrobial susceptibility testing results within 4.5 hours on average.

2024-08

BioSpace

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

Accelerate Diagnostics reported net sales of $2.8 million for the fourth quarter of 2024, a decrease from $3.0 million in the same quarter of the prior year, primarily due to lower consumable product sales.

2025-03

PR Newswire

Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets

Accelerate Diagnostics voluntarily initiated Chapter 11 restructuring proceedings and plans to sell its assets through a court-supervised process, having secured up to $12.5 million in debtor-in-possession (DIP) financing.

2025-05

ElevenFlo

Accelerate Diagnostics: $718M in Losses Ends in 97-Day Credit Bid Sale

Accelerate Diagnostics, after nearly four decades and accumulating $718.9 million in losses by December 2024, filed for Chapter 11 bankruptcy in May 2025, leading to a credit bid sale of its assets to Indaba Capital Management, which then sold them to Bruker Corporation.

2026-03

CAP TODAY

FDA clears Accelerate Arc system

In December 2024, Accelerate Diagnostics announced FDA 510(k) clearance of its Accelerate Arc system and BC kit for use with Bruker's MALDI Biotyper CA system, automating positive blood culture sample preparation.

2024-12

BioSpace

Accelerate Diagnostics Announces Successful Completion of Debt Restructuring Support Agreement, Supporting Advancement of Next-Generation Platform Wave

Accelerate Diagnostics completed a debt restructuring, simplifying its capital structure, extending debt maturity, and securing $24 million in new funding to support the development of its Wave platform.

2023-06

CARB-X

CARB-X is funding Accelerate Diagnostics to develop a rapid optical imaging diagnostic for sepsis and serious antibiotic-resistant bacterial infections

CARB-X awarded Accelerate Diagnostics up to $578,000, with potential for an additional $2.1 million, to develop new fiber optic technology for rapid sepsis diagnosis.

2021-06

Frequently Asked Questions

How does Accelerate Diagnostics' technology improve rapid pathogen identification and Antimicrobial Susceptibility Testing (AST) for critical infections like sepsis?

Accelerate Diagnostics' Phenou2122 system provides rapid pathogen identification (ID) and Antimicrobial Susceptibility Testing (AST) directly from positive blood cultures, significantly reducing turnaround time from days to hours for critical infections like sepsis. This is achieved using fluorescence in situ hybridization (FISH) technology for ID and phenotypic testing for AST, enabling clinicians to optimize antibiotic therapy much faster.

What specific products does Accelerate Diagnostics offer to combat antibiotic resistance, and how do they integrate into existing lab workflows?

Accelerate Diagnostics offers the Accelerate Phenou2122 system and Accelerate PhenoTestu00ae BC kit for integrated rapid ID/AST, and the Accelerate Arcu2122 module and BC kit which automates sample preparation for direct mass spectrometry identification, integrating with existing MALDI platforms. They are also developing the Accelerate WAVEu2122 system for rapid AST. These systems aim to streamline microbiology workflows by providing faster results directly from positive blood cultures.

What are the clinical benefits and potential impact on patient outcomes of using Accelerate Diagnostics' platforms, particularly in the context of sepsis management?

Using Accelerate Diagnostics' platforms can lead to significant clinical benefits, including a reduction in the time to appropriate antibiotic therapy and improved antimicrobial stewardship. Studies have shown a statistically significant reduction in 30-day mortality in certain patient subsets, improved sepsis resolution, and faster de-escalation to narrow-spectrum antibiotics, ultimately enhancing patient outcomes and potentially reducing healthcare costs.

What is the typical pricing model for Accelerate Diagnostics' systems and consumables, and what kind of support and training do they provide to healthcare facilities?

While specific pricing models (e.g., capital equipment cost, reagent rental, cost-per-test) are typically determined through direct consultation, Accelerate Diagnostics aims for solutions that can offer a lower total cost for rapid identification compared to some existing molecular ID solutions. They provide clinical implementation support, outcomes evaluation, and customer education to assist healthcare facilities in integrating and maximizing the benefits of their diagnostic platforms.

How does Accelerate Diagnostics ensure compliance with regulatory standards (e.g., FDA, CLIA) for their diagnostic platforms?

Accelerate Diagnostics ensures compliance by obtaining necessary regulatory clearances for its products, such as the FDA 510(k) clearance for its Accelerate Phenou2122 system, Accelerate PhenoTestu00ae BC kit, and Accelerate Arcu2122 system. The company operates in accordance with CLIA and other federal and state regulations governing laboratory testing. They also actively pursue regulatory clearances for new products, such as the Accelerate WAVEu2122 system.

What is the current financial stability and market position of Accelerate Diagnostics, and what are their key strategic partnerships?

Accelerate Diagnostics has faced significant financial challenges, including an accumulated deficit and negative cash flows, leading to a Chapter 11 bankruptcy filing in May 2025 to sell its assets. Despite these challenges, they have established key strategic partnerships, notably a worldwide commercial collaboration with BD (Becton, Dickinson and Company) for marketing and sales, and a collaboration with Bruker for the Accelerate Arc system.

Related Companies

Suggest an Edit →